{
  "abstract": "Plain Language Summary: What is this summary about?\n\nOsimertinib is an oral (by mouth) medicine that blocks the mutated form of a protein called EGFR on cancer cells, reducing their growth and spread.\n\nOsimertinib is recommended for EGFR-mutated non-small cell lung cancer (NSCLC) after surgery, but its benefit before surgery was unclear.\n\nThe Phase 3 NeoADAURA study examined whether osimertinib alone, or with chemotherapy, before surgery improved outcomes for patients with EGFR-mutated stage 2–3B non-small cell lung cancer.\n\nWhat were the results?\n\n358 patients were randomly assigned to receive either osimertinib plus chemotherapy, osimertinib alone, or placebo plus chemotherapy. Most patients underwent surgery: more than 90% of those who had surgery had all the cancer removed.\n\nThe main result that this study looked at was major pathological response, which is defined as when 10% or fewer live cancer cells can be seen in tissue that is removed during surgery. Among all randomized patients, the proportion of patients achieving a major pathological response was: 26% with osimertinib plus chemotherapy\n\n25% with osimertinib alone\n\n2% with placebo plus chemotherapy.\n\nAfter 1 year, among all randomized patients, 93% who received osimertinib plus chemotherapy, 95% of those receiving osimertinib alone, and 83% receiving placebo plus chemotherapy did not experience cancer worsening or the disease coming back and remained alive. No unexpected safety issues were found.\n\nWhat do the results of the study mean?\n\nIn people living with stage 2–3B, EGFR-mutated non-small cell lung cancer that can be surgically removed, osimertinib treatment with or without chemotherapy before surgery, worked better than placebo plus chemotherapy at reducing the amount of cancer at the time of surgery.\n\nClinical trial number: NCT04351555",
  "abstract_shown": true,
  "affiliations": [
    "Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Centre for Respiratory Disease, Guangzhou, China",
    "Department of Thoracic Surgery, University of Zurich, Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland",
    "State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, The First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China",
    "Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria",
    "Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria",
    "Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan",
    "Division of Pulmonary Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea",
    "Division of Pulmonary Medicine, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan",
    "Vietnam National Lung Hospital, Faculty of Medicine, UMP, VNU, Hanoi, Vietnam",
    "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand",
    "Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China",
    "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China",
    "Department of Medical Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam",
    "Department of Thoracic Oncology, Kanagawa Cancer Canter, Yokohama, Japan",
    "Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China",
    "Orlandi Oncología, Santiago, Chile",
    "Department of Internal Medicine, Pusan National University, School of Medicine, and Yangsan Hospital, Yangsan, Republic of Korea",
    "Clinical Oncology Department, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil",
    "Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK",
    "Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK",
    "Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain",
    "Department of Medicine, University of California, San Francisco, CA, USA",
    "Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA",
    "Department of Diagnostic Pathology, National Cancer Center, Tokyo, Japan",
    "Department of Pathology, Yale School of Medicine, New Haven, CT, USA",
    "Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK",
    "Biometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK",
    "Late-stage Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA",
    "Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
    "Department of Medicine, Weill Cornell Medical College, New York, NY, USA"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 27,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jianxing He"
    },
    {
      "affs": [
        1
      ],
      "name": "Walter Weder"
    },
    {
      "affs": [
        2
      ],
      "name": "Ke-Neng Chen"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Maximilian J. Hochmair"
    },
    {
      "affs": [
        5
      ],
      "name": "Jin-Yuan Shih"
    },
    {
      "affs": [
        6
      ],
      "name": "Sung Yong Lee"
    },
    {
      "affs": [
        7
      ],
      "name": "Kang-Yun Lee"
    },
    {
      "affs": [
        8
      ],
      "name": "Viet Nhung Nguyen"
    },
    {
      "affs": [
        9
      ],
      "name": "Somcharoen Saeteng"
    },
    {
      "affs": [
        10
      ],
      "name": "Lunxu Liu"
    },
    {
      "affs": [
        11
      ],
      "name": "Ligang Xing"
    },
    {
      "affs": [
        12
      ],
      "name": "Nguyen Hoang Gia"
    },
    {
      "affs": [
        13
      ],
      "name": "Shuji Murakami"
    },
    {
      "affs": [
        14
      ],
      "name": "Yongtao Han"
    },
    {
      "affs": [
        15
      ],
      "name": "María Paz Saavedra"
    },
    {
      "affs": [
        16
      ],
      "name": "Seong Hoon Yoon"
    },
    {
      "affs": [
        17
      ],
      "name": "Carlos H.A. Teixeira"
    },
    {
      "affs": [
        18,
        19
      ],
      "name": "Carles Escriu"
    },
    {
      "affs": [
        20
      ],
      "name": "Alex Martinez-Martí"
    },
    {
      "affs": [
        21,
        22
      ],
      "name": "Collin M. Blakely"
    },
    {
      "affs": [
        23
      ],
      "name": "Yasushi Yatabe"
    },
    {
      "affs": [
        24
      ],
      "name": "Sanja Dacic"
    },
    {
      "affs": [
        25
      ],
      "name": "Yuri Rukazenkov"
    },
    {
      "affs": [
        26
      ],
      "name": "Xiangning Huang"
    },
    {
      "affs": [
        27
      ],
      "name": "Anupriya Dayal"
    },
    {
      "affs": [
        28,
        29
      ],
      "name": "Jamie E. Chaft"
    },
    {
      "name": "for the NeoADAURA Investigators"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/640fr5bdpbmkf.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2739188",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13733581/",
  "id": "640fr5bdpbmkf",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2739188",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Plain Language Summary"
    ],
    [
      "heading",
      "Plain Language Summary of Publication"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7224397185",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2739188?needAccess=true",
  "pmcid": "PMC13733581",
  "pmid": "42954342",
  "published": "2026-10-29",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/640fr5bdpbmkf.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:23:19Z",
      "native_id": "PMC13733581",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2739188"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed",
  "title_text": "A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:23:19Z",
  "url": "https://research.draconitic.com/paper/640fr5bdpbmkf",
  "venue": "Future Oncology",
  "versions": []
}